Update 7/29/12: This article was written in 2002.
Poly MVA has since taken
hold and you can read about Dr. James Forsythe, MD, HMD, board certified
oncologist, who started the Cancer Wards at each of the 3 major Nevada hospitals
and ran the Cancer Program at the VA Medical Center, discuss this remarkable
Following is a description of a patented compound
called Polydox or Poly-MVA which appears to meet the criteria of
being non-toxic to normal cells yet lethal to malignant ones.
Tumor Cell Specific Killing
1931, Otto Warburg was awarded a Nobel Prize for being the first to identify
respiratory enzymes and discovering that cancer cell respiration was glycolytic
instead of oxygen dependent. He found that cancer development caused a major
change in energy metabolism.
Based on Warbrug's findings, in 1995, Merrill
Garnett was issued a patent for a novel cancer chemotherapeutic agent which
attacks a target which is only found in malignant cells and is related to
specific changes in energy metabolism. This compound has been named Polydox
(U.S. trials) or Poly-MVA (Canada & Mexico) or LAPd by some researchers. The MVA
stands for minerals, vitamins and aminoacids. LAPd stands for Lipoic Acid /
Cancer is now considered a systematic, as opposed
to a local, disease and its cause is multifactorial. Poly MVA attacks one of the
root causes of cancer. It is a complex of lipoic acid, palladium, B12 and other
B complex vitamins connected to a metal substrate. The complex is very soluble
in water and fat. Therefore it travels all over the body and into every cell. It
is classified as a nucleotide reductase.
Paul M. Bingham of State University of New York's
Department of Biochemistry and Cell Biology clearly demonstrated from a
molecular and cell biological perspective the anti-tumor activity of Poly MVA.
Other therapeutic benefits from these compounds are related to the effect on the
body systems of the antioxidant power of the Lipoic acid and the known benefits
of B-12 and the other B vitamins. These have been reported as increased energy,
improved appetite and pain control measured by reduction of the need for pain
Pharmakon Laboratories performed nude mouse studies using glioblastoma cell line
and the PolyMVA. On day 0, tumor cells were injected subcutaneously in the
scruff of the neck of Swiss-nude mice. When the tumors reached 200 to 400 mm in
volume, the mice were divided into 8 groups of 10 mice. Four groups were dosed
daily I.V., and four groups were dosed daily IP, with either vehicle or test
article at 1.5, 1, or 2 mg/mouse. Mice were dosed for 4 weeks. The volume of
each tumor was determined twice per week.
Necropsies were performed on all animals at
termination of study or when they were found dead. A reduction in tumor size
compared to the vehicle treated group was seen in all groups. This reduction was
statistically significant in the orally treated when the dose was 1 mg/mouse. It
was significant in all the intravenous treated group.
Summary: Based on the data from this study this
synthetic reductase administered orally at 1 mg/mouse or IV at 0.5, 1 or 2
mg/mouse significantly reduced the growth of the glioblastom tumor cell line in
first report of clinical studies of PolyMVA was presented by the late Rudolf E.
Falk, an oncological surgeon at the University of Toronto, in March 1994. Dr.
Falk reported that the compound was administered intravenously, subcutaneously
(under the skin) and per Os in a modified phase 2 study. To quote from Dr.
Falk's summary, "95 patients were treated; these included breast, lung,
colorectal, prostate, pancreatic, ovarian, malignant melanoma and primary brain
neoplasia. 90% of the patients were in the category of having failed all
available therapy. 88 are surviving on therapy with a mean survival time of 9
months. The anticipated survival time of this group, from available statistics
would vary from 20% to 60% at 6 months. All of these patients received moderate
doses of chemotherapy."
The first 27 patients given PolyMVA were all
considered terminal, and all refused to continue with chemotherapy. They were
placed on a "health promotion program" as outlined in
The Definitive Guide to Cancer,
Chapter 23. The cancers involved brain, tongue, esophagus, lung, breast,
stomach, colon, pancreas, prostate, lymph, blood, and marrow. All had
metastasis. All were given 5 drops four times daily as a loading dose. 13
reported improvements in either appetite, weight gain, increased energy or
reduction in pain within the first 7 days of starting PolyMVA. At the end of 14
days 6 additional patients reported improvement. None of the 27 patients
reported adverse reactions.
We learned from this small study (1) that the
initiating dose was inadequate, (2) rapid improvements can be expected in over
60% of patients with a variety of malignant conditions, and (3) PolyMVA is
non-toxic. With this low dose, some patients demonstrated clinical changes
indicating early improvement. A few anecdotal reports follow:
75 year old female with glioblastoma presented
with history of debulking surgeries and 2 rounds of radiation. As a last resort
her cancer center neurologist placed her on massive, experimental doses of
tomoxifen. She entered the hospital in Baja California requiring support on both
arms to walk up the short ramp. Her memory was impaired, she had slurred speech.
Convulsions were under control with dilantin. On the 3rd day after beginning
PolyMVA her memory had improved as had her slurred speech. She walked out of the
hospital unaided to continue therapy at home. She lived 6 months. Her immediate
death is attributable to the side effects of the tamoxifen which she continued
to take before and after the PolyMVA.
Glioblastoma patients usually have a dramatic,
early response similar to Mr. D. age 66. His tumor inactivated his right leg and
foot and caused generalized convulsions which were poorly controlled by tegretol,
or dilantin. I received a phone call from Mr. D. four days after he began
PolyMVA. He said his paralysis was gone and he could walk outside and water the
lawn and ride his stationary bicycle. Eight days after beginning he called again
to report that his convulsions were now localized and almost gone.
Pain from metastatic breast cancer to the spine
and right hip in CF age 56 required a right hip replacement which gave relief
from hip pain, but did not effect the spine. She started PolyMVA and within 2
weeks her "back pain stopped" and she returned to her legal research employment.
Most breast cancer patients report at least temporary improvement.
Two cases of cancer of esophagus requiring MS for
pain relief, cachectic and terminal when they started PolyMVA. Mr. G. age 62 was
in a Mexican hospital when he was scheduled to began the PolyMVA. LS age 45 took
the PolyMVA for home use. Mr. G died within 6 weeks, but an investigation
uncovered the fact hat he was never given the PolyMVA. He was given Laetril
alone. LS reported increased strength and weight gain and is still living (2
years from starting PolyMVA).
Diagnosed in April 1995 a female multiple myeloma
patient from Alaska with two degrees, a Ph.D. and J.D. sent us a letter dated
March 1997 that after taking PolyMVA her blood tests and examinations showed "
no measurable signs of multiple myeloma carcinoma" and her doctors said "She is
in total remission."
Colon cancer patients with obstruction reported
improvement using the PolyMVA by enema. This is logical since PolyMVA is
soluable in fat and liquid.
current scientific studies for the cure of cancer using destructive methods has
not been entirely successful and should be supplemented with health supporting
therapeutics and individual response reports (anecdotal data).
These studies indicate that no patient should be
consigned to a "terminal classification" until no improvement is measured after
a trial with PolyMVA and other health supporting measures.
Successful individual outcomes using the new
paradigm of health support versus cancer cell destruction are reported. A
new cancer compound which exclusively kills cancer cells based upon Warburg's
cancer cell respiration physiology was discussed. There is an overwhelming need
for studies using PolyMVA in stages one and two malignancies with and without
destructive methods. See note below.
Who Developed it and what it can do for you?
Albert Sanchez, Orange County school principal, vowed to his dying wife to
relentlessly search for a cure for cancer, he never expected to find it. His
sometimes frightening but eventful life finally led him to PolyMVA, a non-toxic
antioxidant composed of alpha lipoic acid and palladium. This super nutrient,
developed in the U.S. by Dr. M. Garnett, the discoverer of the 2nd Genetic Code,
has already shown extraordinary healing abilities for degenerative diseases,
Dr. Sanchez, CEO of several international pharmaceutical companies, shares with
us his dream of finding a cure to life-threatening disease in his plan of
creating a free University Hospital for the study of cancer. His wish to explain
what this discovery offers and why doctors and veterinarians across the world
are already using this product has led him to the podium of many lecture halls
Dr. Albert Sanchez has been focused on sharing information about the super
antioxidant PolyMVA ever since realizing its significance. He is the author of
several books and an accomplished speaker. He's available for daily phone
interviews, for advice or to answer any of your questions. Telephone: (619)
see: Chinese Herb Triumphs Over
CANCER + The Link
between CANCER and
Blood Type +
Prostate CANCER: Facts You
Should Know + several CANCER
articles on the Index page below.
NOTE: Before PolyMVA, the father of
alternative medicine in Germany, Dr. Josef Issels, reported 18.5% of the
terminal patients he treated lived 5 years or longer. There are many Alternative
Physicians in the United States achieving similar results. Issels' treatments
were health supporting as opposed to the current cancer destructive methods. Our
use with PolyMVA has been limited to three years. In almost all cancers where
the product was used the patients reported symptom improvement. More studies are
necessary to assess the extent it prolongs life. PolyMVA can be used as an
adjuvant to cancer destruction methods with great benefit to the patient. But
for best results it is used with other health supporting regimens.
For further understanding of how the
oxidation-reduction reactions and the hydrogen donor mechanisms provided by
PolyMVA work, please refer to Understanding the Redox (rHS) Measurement of the
Biological Terrain by Robert C. Greenberg. TLfDP Aug-Sept 1997. P. 64-68